More research is currently inquiring about the efficacy of targeting VEGF in medications for HHT patients to inhibit angiogenesis, given that HHT patients often have an active pro-angiogenesis process [133]. Here, VEGFA is linked to hereditary hemorrhagic telangiectasia.